The e antigen of the Hepatitis B virus enables evasion of Type 1 Interferon immune response

2017 ◽  
Vol 66 (1) ◽  
pp. S702
Author(s):  
Z. Valaydon ◽  
G. Ebert ◽  
M. Pellegrini ◽  
P. Desmond ◽  
T. Sozzi ◽  
...  
Keyword(s):  
Immune Response ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Type 1 Interferon ◽  
B Virus

scholarly journals A Hepatitis B Virus-Derived Peptide Can Inhibit Infection of Human Lung Cells with SARS-CoV-2 in a Type-1 Interferon-Dependent Manner

Viruses ◽  
2021 ◽  
Vol 13 (7) ◽  
pp. 1227
Author(s):  
Yu-Min Choi ◽  
Hyein Jeong ◽  
Uni Park ◽  
Nam-Hyuk Cho ◽  
Bum-Joon Kim
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Antiviral Effect ◽  
Epithelial Cell Line ◽  
Dependent Manner ◽  
Type 1 Interferon ◽  
Human Lung Cells ◽  
B Virus ◽  
Hiv 1

The current COVID-19 pandemic has highlighted the urgent need to develop effective therapeutic strategies. We evaluated the in vitro antiviral effect against SARS-CoV-2 of a hepatitis B virus (HBV) hexamer peptide, Poly6, which is capable of eliciting an antiviral effect against human immunodeficiency virus -1 (HIV-1), as a novel HIV-1 integrase inhibitor, and a strong anticancer immune response in an IFN-I-dependent manner, as a novel potential adjuvant in anticancer immunotherapy. Here, we report that Poly6 exerts an anti-SARS-CoV-2 effect, with an estimated 50% inhibitory concentration of 2.617 µM, in the human bronchial epithelial cell line, Calu-3 but not in Vero-E6 cells, which are deficient in type 1 interferon (IFN-I) signaling. We proved via assays based on mRNA profiles, inhibitors, or blocking antibodies that Poly6 can exert an anti-SARS-CoV-2 effect in an IFN-I-dependent manner. We also found that Poly6 inhibits IL-6 production enhanced by SARS-CoV-2 in infected Calu-3 cells at both the transcription and the translation levels, mediated via IL-10 induction in an IFN-I-dependent manner. These results indicate the feasibility of Poly6 as an IFN-I-inducing COVID-19 drug with potent antiviral and anti-inflammatory activities.

How Far we are towards Eradication of HBV Infection

2015 ◽  
Vol 24 (4) ◽  
pp. 473-479 ◽  
Author(s):  
Mihai Voiculescu
Keyword(s):  
Immune Response ◽  
Hepatitis B Virus ◽  
T Cell ◽  
Hepatitis B ◽  
T Cell Receptors ◽  
Hepatitis B Surface Antigen ◽  
Hbv Infection ◽  
Major Health Problem ◽  
Cell Receptors ◽  
B Virus

Hepatitis B virus (HBV) infection is a major health problem with an important biological and a significant socio-economic impact all over the world. There is a high pressure to come up with a new and more efficient strategy against HBV infection, especially after the recent success of HCV treatment. Preventing HBV infection through vaccine is currently the most efficient way to decrease HBV-related cirrhosis and liver cancer incidence, as well as the best way to suppress the HBV reservoir. The vaccine is safe and efficient in 80-95% of cases. One of its most important roles is to reduce materno-fetal transmission, by giving the first dose of vaccine in the first 24 hours after birth. Transmission of HBV infection early in life is still frequent, especially in countries with high endemicity.Successful HBV clearance by the host is immune-mediated, with a complex combined innate and adaptive cellular and humoral immune response. Different factors, such as the quantity and the sequence of HBV epitope during processing by dendritic cells and presenting by different HLA molecules or the polymorphism of T cell receptors (TOL) are part of a complex network which influences the final response. A new potential therapeutic strategy is to restore T-cell antiviral function and to improve innate and adaptive immune response by immunotherapeutic manipulation.It appears that HBV eradication is far from being completed in the next decades, and a new strategy against HBV infection must be considered. Abbreviations: ALT: alanine aminotransferase; APC: antigen presenting cells; cccDNA: covalently closed circular DNA; HBIG: hepatitis B immunoglobulin; HbsAg: hepatitis B surface antigen; HBV: hepatitis B virus; HCC: hepatocellular carcinoma; CTL: cytotoxic T lymphocyte; IFN: interferon; NUC: nucleos(t)ide analogues; pg RNA: pre genomic RNA; TLR: toll-like receptors; TOL: T cell receptors.

scholarly journals Immune Response to Hepatitis B Virus in Children with Papular Acrodermatitis

1977 ◽  
Vol 73 (5) ◽  
pp. 1103-1106 ◽  
Author(s):  
M. Colombo ◽  
M.A. Gerber ◽  
S.J. Vernace ◽  
F. Gianotti ◽  
F. Paronetto
Keyword(s):  
Immune Response ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
B Virus

Cellular immune response to hepatitis B virus antigens

1988 ◽  
Vol 7 (1) ◽  
pp. 21-33 ◽  
Author(s):  
C. Ferrari ◽  
A. Penna ◽  
A. DegliAntoni ◽  
F. Fiaccadori
Keyword(s):  
Immune Response ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Cellular Immune Response ◽  
B Virus ◽  
Hepatitis B Virus Antigens ◽  
Virus Antigens ◽  
Cellular Immune

scholarly journals Synthesis of 4′-Substituted Purine 2′-Deoxynucleosides and Their Activity against Human Immunodeficiency Virus Type 1 and Hepatitis B Virus

2018 ◽  
Vol 3 (11) ◽  
pp. 3313-3317 ◽  
Author(s):  
Satoru Kohgo ◽  
Shuhei Imoto ◽  
Ryoh Tokuda ◽  
Yuki Takamatsu ◽  
Nobuyo Higashi-Kuwata ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Human Immunodeficiency Virus Type ◽  
Virus Type ◽  
B Virus ◽  
Immunodeficiency Virus

scholarly journals Evaluation of Anti-HBs Antibody Immune Response against Hepatitis B virus in Vaccinated People in а North-eastern Bulgaria Region

Folia Medica ◽  
2019 ◽  
Vol 61 (4) ◽  
pp. 572-578
Author(s):  
Denitsa T. Tsaneva-Damyanova ◽  
Liliya I. Ivanova ◽  
Silviya N. Pavlova ◽  
Svetlana B. Todorova ◽  
Tsvetelina K. Popova
Keyword(s):  
Immune Response ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Age Groups ◽  
University Hospital ◽  
Human Pathogens ◽  
Serum Samples ◽  
Post Vaccination ◽  
B Virus ◽  
Mass Immunization

Introduction: Hepatitis B virus (HBV) is one of the most significant human pathogens responsible for a huge number of acute and chronic liver infectious diseases worldwide. Aim: To find the duration of post-vaccination immune response in individuals allocated to five age groups from 6 months to 20 years. Materials and methods: All tested subjects were born between 1999 and 2018 and therefore covered by the compulsory vaccination program against hepatitis B. For the serological marker anti-HBs Ab we investigated 449 serum samples taken from ambulatory people and patients of St Marina University Hospital in Varna. Results: A positive antibody response (anti-HBs Ab > 10 mIU/ml) was reported in 79.7% (n = 51) of the group of subjects up to one year old, in 70.0% (n = 196) of the subjects in the age range 1 year/1 month to 15 years, and in 39.3% (n = 33) of the subjects 15 years/1 month to 20 years old. Female sex had a better post-vaccination response than male sex with statistically significant relationship between sex and anti-HBs Ab titer (&chi;2 = 24.76, p <0.01). Conclusions: Regardless of the mass immunization against HBV in Bulgaria, the relative share of chronic HBV infections does not show a downward trend. Therefore, it is very important to study the duration of the post-vaccination immune response by demonstrating the anti-HBs antibodies and to apply a booster dose from the vaccine if needed.

The enhanced immune response of hepatitis B virus DNA vaccine using SiO2@LDH nanoparticles as an adjuvant

Biomaterials ◽  
2014 ◽  
Vol 35 (1) ◽  
pp. 466-478 ◽  
Author(s):  
Jin Wang ◽  
Rongrong Zhu ◽  
Bo Gao ◽  
Bin Wu ◽  
Kun Li ◽  
...  
Keyword(s):  
Immune Response ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Dna Vaccine ◽  
Hepatitis B Virus Dna ◽  
B Virus
Sign in / Sign up

Export Citation Format

Share Document